MRI诊断肝脏影像报告和数据系统v2018版LR-M观察灶:系统综述与Meta分析
该系统综述与Meta分析纳入18项研究、共3615例患者的3812个LR-M观察灶,评估MRI上LR-M类中肝细胞癌(HCC)与非HCC恶性肿瘤的概率及LR-M影像特征频率。LR-M观察灶中HCC汇总百分比为29%(95%CI 21-38%),非HCC恶性肿瘤为67%(95%CI 57-77%),恶性肿瘤总体为96%,良性病变为4%。10个LR-M影像特征中,环形动脉期高强化(APHE)在非HCC恶性肿瘤中频率最高(68%;95%CI 61-75%)。
要点
- LR-M观察灶中非HCC恶性肿瘤占67%,但HCC仍占29%,LR-M并非非HCC肿瘤专属。
- 环形动脉期高强化在非HCC恶性肿瘤中频率最高(68%;95%CI 61-75%)。
- 研究类型和是否纳入良性病变是研究间异质性的显著影响因素。
核心结论
- LR-M类别常用于描述非HCC恶性肿瘤,但也包含29%的HCC;不同LR-M影像特征频率各异,环形APHE在非HCC恶性肿瘤中频率最高。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE和EMBASE数据库2018年1月1日至2021年3月16日发表的文献,纳入18项报告MRI上LR-M类诊断性能的研究(3615例患者、3812个观察灶),其中9项研究报告LR-M影像特征频率;采用QUADAS-2工具评估偏倚风险和适用性关注。
关键影像表现/征象
- LR-M观察灶中HCC汇总百分比为29%(95%CI 21-38%)。
- LR-M观察灶中非HCC恶性肿瘤汇总百分比为67%(95%CI 57-77%)。
- 10个LR-M影像特征中,环形动脉期高强化在非HCC恶性肿瘤中频率最高(68%;95%CI 61-75%)。
诊断标准与关键数值
- LR-M观察灶中恶性肿瘤总体汇总百分比为96%,其中HCC为29%、非HCC恶性肿瘤为67%,良性病变为4%。
- 环形动脉期高强化在非HCC恶性肿瘤中的频率为68%(95%CI 61-75%)。
- 研究类型和纳入良性病变是研究异质性的显著影响因素。
临床应用与阅片要点
- MRI上判读为LR-M的观察灶中,非HCC恶性肿瘤占多数(67%),但HCC仍占29%,报告时需结合环形APHE等特征综合评估。
局限性
- 研究类型和纳入良性病变是研究间异质性的显著影响因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: We performed a meta-analysis to determine the probability of hepatocellular carcinoma (HCC) and non-HCC malignancies in Liver Imaging Reporting and Data System (LI-RADS) category M (LR-M) observations and the frequency of defined LR-M imaging features on MRI using LI-RADS v2018.
METHODS: We searched the MEDLINE and EMBASE databases to identify studies published from 1 January 2018 to 16 March 2021 reporting the probability of category LR-M in HCC and non-HCC malignancies on MRI. The pooled percentages of HCC and non-HCC malignancies in the LR-M observations were evaluated. Meta-regression analysis was performed to identify factors for study heterogeneity. The frequencies of defined LR-M imaging features were also calculated. Risk of bias and concerns regarding applicability were evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 tool.
RESULTS: We identified 18 studies reporting the diagnostic performance of the LR-M category (3,812 observations in 3,615 patients), with nine studies reporting the frequencies of LR-M imaging features. The pooled percentages of HCC and non-HCC malignancies in the LR-M observations were 29% (95% confidence interval [CI], 21-38%) and 67% (95%CI, 57-77%), respectively. The study type and inclusion of benign lesions were significant factors for study heterogeneity. Of the 10 LR-M imaging features, rim arterial phase hyperenhancement (APHE) showed the highest frequency in non-HCC malignancies (68%; 95%CI, 61-75%).
CONCLUSIONS: The LR-M category was commonly used to characterize non-HCC malignancies, but also included 29% of HCC. The frequencies of the different LR-M imaging features were variable, with rim APHE showing the highest frequency in non-HCC malignancies.
KEY POINTS: • In the LR-M category using LI-RADS v2018 for MRI, the pooled percentage of malignancies in general was 96%, with 29% HCC and 67% non-HCC malignancies, while the remaining 4% was benign entity. • The study type and inclusion of benign lesions were significant factors contributing to substantial heterogeneity among included studies. • The frequencies of the different LR-M imaging features were variable, with rim APHE showing the highest frequency in non-HCC malignancies.
引用
- Shin J, Lee S, Hwang JA, et al. MRI-diagnosis of category LR-M observations in the Liver Imaging Reporting and Data System v2018: a systematic review and meta-analysis. Eur Radiol. 2022. PMID: 35031839. doi:10.1007/s00330-021-08382-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。